Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in premenopausal women

Chen, Hengxi; Li, Xiao; Li, Jie; Cui, Ling; Huang, Wei

doi:10.1002/14651858.cd008018.pub3

Cited by 55 publications

(40 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A previous meta-analysis of six studies that included clinically established markers of ovarian reserve, as estimated by the hormone dosage of AMH, which is the gold standard for this estimation, reported no improvement in ovarian markers though higher rates of recovery of menses in the GnRHa group, and no differences in pregnancy rates or fertility were found between the groups [141]. In line with these results, a recent Cochrane systematic review pointed out that there was insufficient evidence of fertility protection from GnRHa [142]. Of note, the 2018 panel of the American Society of Clinical Oncology, ASCO, recommended that GnRHa should not be used in place of proven fertility preservation methods [143].…”

Section: Potential Protective Treatments To Reduce/recover Chemothmentioning

confidence: 97%

Ovarian Follicle Depletion Induced by Chemotherapy and the Investigational Stages of Potential Fertility-Protective Treatments—A Review

Hao

Anastácio

Liu

et al. 2019

IJMS

View full text Add to dashboard Cite

Ovarian follicle pool depletion, infertility, and premature menopause are all known sequelae of cancer treatment that negatively impact the quality of life of young cancer survivors. The mechanisms involved in this undesired iatrogenic ovarian damage have been intensively studied, but many of them remain unclear. Several chemotherapeutic drugs have been shown to induce direct and indirect DNA-damage and/or cellular stress, which are often followed by apoptosis and/or autophagy. Damage to the ovarian micro-vessel network induced by chemotherapeutic agents also seems to contribute to ovarian dysfunction. Another proposed mechanism behind ovarian follicle pool depletion is the overactivation of primordial follicles from the quiescent pool; however, current experimental data are inconsistent regarding these effects. There is great interest in characterizing the mechanisms involved in ovarian damage because this might lead to the identification of potentially protective substances as possible future therapeutics. Research in this field is still at an experimental stage, and further investigations are needed to develop effective and individualized treatments for clinical application. This review provides an overview of the current knowledge and the proposed hypothesis behind chemotherapy-induced ovarian damage, as well as current knowledge on possible co-treatments that might protect the ovary and the follicles from such damages.

show abstract

Section: Potential Protective Treatments To Reduce/recover Chemothmentioning

confidence: 97%

Ovarian Follicle Depletion Induced by Chemotherapy and the Investigational Stages of Potential Fertility-Protective Treatments—A Review

Hao

Anastácio

Liu

et al. 2019

IJMS

View full text Add to dashboard Cite

show abstract

“…However, more recent studies report conflicting results and emerging data on longer term follow-up fail to demonstrate a significant impact on future pregnancy rates, so there is insufficient evidence to recommend GnRHa for this indication alone. (Clowse et al, 2009;Chen et al, 2011;Turner et al, 2013;Del Mastro et al, 2014;Blumenfeld et al, 2015;Shen et al, 2015;Demeestere et al, 2016;Munhoz et al, 2016).…”

Section: Choice Of Therapy For Menstrual Suppression During Cancer Trmentioning

confidence: 99%

BSH Guideline: management of thrombotic and haemostatic issues in paediatric malignancy

et al. 2018

View full text Add to dashboard Cite

“…76 A Cochrane review concluded that use of adjuvant gonadotrophin-releasing hormone (GnRH) agonists reduced the risk of chemotherapy-induced POI (RR: 0.44, 95% CI: 0.31-0.61). 78 Pelvic irradiation and radiotherapy doses more than 9 to 10 Gray confer an increased risk of POI with the greatest risk observed in postpubertal patients receiving alkylating chemotherapy and radiotherapy (RR: 29.3, 95% CI: 7.9-108). 10,14,75 Surgery may also cause POI/early menopause either due to direct excision of ovaries or due to disruption of gonadal blood supply during pelvic surgery.…”

Section: Iatrogenic Factorsmentioning

confidence: 99%

Prevalence and Risk Factors of Premature Ovarian Insufficiency/Early Menopause

Giri

Vincent

2020

Semin Reprod Med

View full text Add to dashboard Cite

Premature ovarian insufficiency (POI) and early menopause, defined as loss of ovarian activity prior to 40 years or menopause between the ages of 40 and 45 years, respectively, is associated with significant adverse health impacts. Recent data indicate that the prevalence of POI and early menopause is greater than was previously thought, affecting more than 10% of women. Biopsychosocial risk factors including genetic, autoimmune, reproductive, lifestyle, early-life, social/environmental, and iatrogenic have been associated with POI/early menopause or earlier age at menopause. However, establishing a causal role and the underlying mechanisms remains elusive. Understanding and clarification of these risk factors will facilitate prevention and risk minimization strategies to optimize women's health.

show abstract

Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in premenopausal women

Abstract: Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in premenopausal women.

Cited by 55 publications

References 61 publications

Ovarian Follicle Depletion Induced by Chemotherapy and the Investigational Stages of Potential Fertility-Protective Treatments—A Review

Ovarian Follicle Depletion Induced by Chemotherapy and the Investigational Stages of Potential Fertility-Protective Treatments—A Review

BSH Guideline: management of thrombotic and haemostatic issues in paediatric malignancy

Prevalence and Risk Factors of Premature Ovarian Insufficiency/Early Menopause

Contact Info

Product

Resources

About